Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




A Transcriptional Co-Repressor Protein Links Obesity to Breast Cancer Risk

By LabMedica International staff writers
Posted on 28 Feb 2013
Weight gain and high-carbohydrate diets increase risk of developing breast cancer due to the activity of the transcriptional co-repressor protein CtBP (C-terminal binding protein).

The CtBP protein family has gained wide scientific interest due to findings that identified its critical role in animal development and oncogenesis. More...
These multifunctional proteins predominantly function as transcriptional co-repressors in the nucleus by recruiting various histone-modifying enzymes such as histone deacetylases, histone methylases, and a histone demethylase. They also perform several diverse cytosolic functions such as Golgi maintenance and in central nervous system synapses.

Investigators at the [US] National Cancer Institute (Bethesda, MD, USA) used advanced genomic techniques to profile levels of CtBP in breast cancer cells. They reported in the February 5, 2013, online edition of the journal Nature Communications that elevated levels of CtBP in patient tumors predicted shorter survival time.

A high level of CtBP was found to drive epithelial-to-mesenchymal transition, stem cell pathways, and genome instability. Depletion of CtBP or caloric restriction reversed gene repression and increased DNA repair. Several members of the CtBP-targeted gene network were selectively downregulated in aggressive breast cancer subtypes. This group included the BRCA1 tumor suppressor gene. Both CtBP promoter targeting and gene repression could be reversed by small molecule inhibition.

“Our new work suggests that targeting CtBP may provide a way of treating breast cancer and possibly preventing breast cancer,” said senior author Dr. Kevin Gardner, head of the transcription regulation section at the [US] National Cancer Institute. “Modifying diet and maintaining a healthy diet, combined with developing pharmacological ways of lessening CtBP activity may one day lead to a way to break the link between cancer and obesity. Research should continue to focus on the link between obesity, CtBP, and breast cancer. This will require more population-based studies and multidisciplinary teams of scientist to investigate these links.”

Related Links:

National Cancer Institute



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.